AUSTRIA and Germany will become the first markets in the European Union to launch Alzhemier's drug Leqembi (lecanemab, Eisai).
The TGA knocked back Eisai's application to register the anti-amyloid monoclonal antibody in Australia (PD 04 Mar), citing safety and efficacy concerns.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Aug 25